Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum

We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Timothy A., Leier, Hans C., Lyski, Zoe L., McBride, Savannah K., Coulter, Felicity J., Weinstein, Jules B., Goodman, James R., Lu, Zhengchun, Siegel, Sarah A. R., Sullivan, Peter, Strnad, Matt, Brunton, Amanda E., Lee, David X., Curlin, Marcel E., Messer, William B., Tafesse, Fikadu G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043482/
https://www.ncbi.nlm.nih.gov/pubmed/33851185
http://dx.doi.org/10.1101/2021.04.04.21254881
Descripción
Sumario:We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced levels of neutralization by vaccinated and convalescent sera. Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.

Ejemplares similares